The Cancer Letter

Inside information on cancer research and drug development

Clinical

In early results “unprecedented in rectal cancer,” 14/14 patients show clinical complete response to dostarlimab

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

EC approves Fruzaqla for previously-treated mCRC

The European Commission approved Fruzaqla (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. 
Guest Editorial

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi
Byline
Alice Tracey
Alice Tracey
Reporter
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account